BIMINI Biotech develops novel therapeutics for hematologic malignancies by modulating the hematopoietic‑specific Wiskott‑Aldrich‑Syndrome Protein (WASp), including lead agonist BM‑011 licensed from the Institute of Oncology Research. The Leiden‑based company combines entrepreneurial and scientific expertise and closed a €3m seed round in 2025 to advance its first‑in‑class lymphoma programs.